<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818907</url>
  </required_header>
  <id_info>
    <org_study_id>Pancreas-CGE</org_study_id>
    <nct_id>NCT02818907</nct_id>
  </id_info>
  <brief_title>Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable</brief_title>
  <acronym>Pancreas-CGE</acronym>
  <official_title>Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable : a Multicentre Prospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancéropôle Grand-Est</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <brief_summary>
    <textblock>
      This study aims to collect clinical, biological and quality of life data from patients with a&#xD;
      borderline or resectable pancreatic cancer. It will collect information from the date of&#xD;
      diagnosis along the therapeutic care of the patients, and a 3-years follow-up after the end&#xD;
      of the treatment. The database will be updated at each patient's visit. Biological samples&#xD;
      will include: tumor, and plasma. Epidemiological data will also be collected, whereas Quality&#xD;
      of life will be assessed by the EORTC standard. The objectives of this database are to&#xD;
      identify new biomarkers (genomic, immunologic, and epidemiologic) and promote high quality&#xD;
      standard research protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014)</measure>
    <time_frame>date of first disease apparition [within 3 years after the enrollment of the last patient]</time_frame>
    <description>DATECAN = Definition for the Assessment of Time-to-event Endpoints in CANcer trials</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Additional biological samples</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.&#xD;
Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.&#xD;
Tumor tissue will be collected during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional biological samples</intervention_name>
    <description>blood and tumor tissue samples</description>
    <arm_group_label>Additional biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with exocrine resectable pancreatic adenocarcinoma or potentially resectable&#xD;
             (that after neoadjuvant treatment are considered appropriate candidates for resection)&#xD;
&#xD;
          -  Histologically or cytologically documented diagnosis of exocrine pancreatic&#xD;
             adenocarcinoma&#xD;
&#xD;
          -  Written informed consent obtained prior enrollment in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other types of pancreatic cancer, in particular endocrine tumor or acinar cells&#xD;
&#xD;
          -  ampulloma&#xD;
&#xD;
          -  metastatic disease&#xD;
&#xD;
          -  other malignancy within the last 5 years, except for adequately treated carcinoma in&#xD;
             situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  patient with any medical or psychiatric condition or disease which would make the&#xD;
             patient inappropriate for entry into this study&#xD;
&#xD;
          -  patient under guardianship, curator or under the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno HEYD, Pr</last_name>
    <email>bruno.heyd@univ-fcomte.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe BORG, Pr</last_name>
    <email>christophe.borg@efs.sante.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BORG, Pr</last_name>
      <email>christophe.borg@efs.sante.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno HEYD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, Pr</last_name>
    </contact>
    <investigator>
      <last_name>François GHIRINGHELLI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick RAT, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Patrick RAT, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain MANFREDI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmet AYAV, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Ahmet AYAV, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry CONROY, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Thierry CONROY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Reza KIANMANESH, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Ali Reza KIANMANESH, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick DUFOUR, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Patrick DUFOUR, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg - Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BACHELLIER, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Philippe BACHELLIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

